SIStanley C. Igwe

Stanley C. Igwe

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Stanley C. Igwe has a total of 56 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Epidemiology of Epilepsy in Nigeria

    by Musa M. Watila, Salisu A. Balarabe, Morenikeji A. Komolafe, Stanley C. Igwe, Michael B. Fawale, Willem M. Otte, Eric van Diessen, Olaitan Okunoye, Anthony A. Mshelia, Ibrahim Abdullahi, et al.

    Background We determined the prevalence, incidence, and risk factors for epilepsy in Nigeria. Methods We conducted a door-to-door survey to identify cases of epilepsy in 3 regions. We estimated age-standardized prevalence adjusted for nonresponse and sensitivity and the 1-year retrospective incidence for active epilepsy. To assess potential risk factors, we conducted a case-control study by collecting sociodemographic and risk factor data. We estimated odds ratios using logistic regression analysis and corresponding population attributable fractions (PAFs). Results We screened 42,427 persons (age ≥6 years), of whom 254 had confirmed active epilepsy. The pooled prevalence of active epilepsy per 1,000 was 9.8 (95% confidence interval [CI] 8.6–11.1), 17.7 (14.2–20.6) in Gwandu, 4.8 (3.4–6.6) in Afikpo, and 3.3 (2.0–5.1) in Ijebu-Jesa. The pooled incidence per 100,000 was 101.3 (95% CI 57.9–167.6), 201.2 (105.0–358.9) in Gwandu, 27.6 (3.3–128.0) in Afikpo, and 23.9 (3.2–157.0) in Ijebu-Jesa. Children9s significant risk factors included febrile seizures, meningitis, poor perinatal care, open defecation, measles, and family history in first-degree relatives. In adults, head injury, poor perinatal care, febrile seizures, family history in second-degree relatives, and consanguinity were significant. Gwandu had more significant risk factors. The PAF for the important factors in children was 74.0% (71.0%–76.0%) and in adults was 79.0% (75.0%–81.0%). Conclusion This work suggests varied epidemiologic numbers, which may be explained by differences in risk factors and population structure in the different regions. These variations should differentially determine and drive prevention and health care responses.


  • Complementary and alternative medicine in epilepsy: A global survey of physicians’ opinions

    by Ali A. Asadi-Pooya, Francesco Brigo, Simona Lattanzi, Ioannis Karakis, Marjan Asadollahi, Eugen Trinka, Lobna Talaat El Ghoneimy, Chrisma Pretorius, Guilca Contreras, Anilu Daza-Restrepo, et al.


  • Translation and validation of an epilepsy-screening questionnaire in three Nigerian languages

    by Musa M. Watila, Salisu A. Balarabe, Morenikeji Komolafe, Stanley C. Igwe, Michael Bimbo Fawale, Eric van Diessen, Yakub W. Nyandaiti, Gagandeep Singh, Andrea S. Winkler, Josemir W. Sander


  • Open Access

    Does Melatonin and Melatonin Agonists Improve the Metabolic Side Effects of Atypical Antipsychotics?: A Systematic Review and Meta-analysis of Randomized Controlled Trials

    by Stanley C. Igwe, Francesco Brigo

    Stanley C. Igwe, Francesco Brigo. Clin Psychopharmacol Neurosci 2018;16:235-45. https://doi.org/10.9758/cpn.2018.16.3.235


  • Stiripentol for focal refractory epilepsy

    by Francesco Brigo, Monica Storti, Stanley C Igwe

    This is an updated version of the original Cochrane review published in 2014 (Issue 1). For nearly 30% of people with epilepsy, seizures are not controlled by current treatments. Stiripentol is a new antiepileptic drug (AED) that was developed in France and was approved by the European Medicines Agency (EMA) in 2007 for the treatment of Dravet syndrome as adjunctive therapy with valproate and clobazam, with promising effects. To evaluate the efficacy and tolerability of stiripentol as add-on treatment for patients with focal refractory epilepsy who are taking AEDs. We searched the Cochrane Epilepsy Group Specialised Register (10 August 2015), the Cochrane Central Register of Controlled Trials (CENTRAL; August 2015, Issue 8)and MEDLINE (Ovid) (1946 to 10 August 2015). We contacted Biocodex (the manufacturer of stiripentol) and epilepsy experts to identify published, unpublished and ongoing trials. Randomised controlled add-on trials of stiripentol in patients with focal refractory epilepsy. Review authors independently selected trials for inclusion and extracted data. Outcomes investigated included 50% or greater reduction in seizure frequency, seizure freedom, adverse effects, treatment withdrawal and changes in quality of life. On the basis of our selection criteria, we included no new studies in the present review. However, we did include one study from the earlier review (32 children with focal epilepsy). This study adopted a 'responder enriched' design and found no clear evidence of a reduction in seizure frequency (≥ 50% seizure reduction) (risk ratio (RR) 1.51, 95% confidence interval (CI) 0.81 to 2.82) nor evidence of seizure freedom (RR 1.18, 95% CI 0.31 to 4.43) when add-on stiripentol was compared with placebo. Stiripentol led to a greater risk of adverse effects considered as a whole (RR 2.65, 95% CI 1.08 to 6.47). When specific adverse events were considered, confidence intervals were very wide and showed the possibility of substantial increases and small reductions in risks of neurological (RR 2.65, 95% CI 0.88 to 8.01) or gastrointestinal adverse effects (RR 11.56, 95% CI 0.71 to 189.36). Researchers noted no clear reduction in the risk of study withdrawal (RR 0.66, 95% CI 0.30 to 1.47), which was high in both groups (35.0% in add-on placebo and 53.3% in stiripentol group). The external validity of this study was limited because only responders to stiripentol (i.e. patients experiencing a ≥ 50% decrease in seizure frequency compared with baseline) were included in the randomised add-on placebo-controlled double-blind phase. Furthermore, carry-over and withdrawal effects probably influenced outcomes related to seizure frequency. Very limited information derived from the only included study shows that adverse effects considered as a whole seemed to occur significantly more often with add-on stiripentol than with add-on placebo. Since the last version of this review was published, we have found no new studies. Hence, we have made no changes to the conclusions of this update as presented in the initial review. We can draw no conclusions to support the use of stiripentol as add-on treatment for focal refractory epilepsy. Additional large, randomised, well-conducted trials are needed.


  • Open Access

    Terminology of psychogenic nonepileptic seizures

    by Francesco Brigo, Stanley C. Igwe, Harald Ausserer, Raffaele Nardone, Frediano Tezzon, Luigi Giuseppe Bongiovanni, Michele Tinazzi, Eugen Trinka

    Summary: Several different terms have been used to describe “psychogenic nonepileptic seizures” (PNES) in the literature. In this study, we evaluated the most common English terms used to describe PNES on Google and in PubMed using multiple search terms (https://www.google.com and http://www.ncbi.nlm.nih.gov/pubmed). The information prevalence of the five terms most frequently used to refer to PNES in PubMed were: psychogenic non(‐)epileptic seizure(s), followed by pseudo(‐)seizure(s), non(‐)epileptic seizure(s), psychogenic seizure(s), and non(‐)epileptic event(s). The five most frequently adopted terms to describe PNES in Google were: psychogenic non(‐)epileptic seizure(s), followed by non(‐)epileptic event(s), psychogenic attack(s), non(‐)epileptic attack(s), and psychogenic non(‐)epileptic attack(s). The broad spectrum of synonyms used to refer to PNES in the medical literature reflects a lack of internationally accepted, uniform terminology for PNES. In addition to “seizure(s),” lay people use the word “attack(s)” to describe PNES. Although considered obsolete, some terms, e.g., pseudoseizure(s), are still used in the recent medical literature. Adopting a uniform terminology to describe PNES could facilitate communication between epileptologists, physicians without specific expertise in epilepsy, and patients.


  • Patterns of diagnosis and therapeutic care of epilepsy at a tertiary referral center in Nigeria

    by Stanley C. Igwe, Francesco Brigo, Omeiza Beida

    Summary: Objective: Epilepsy care in developing countries is challenged by the paucity of trained specialists, diagnostic tools, and antiepileptic drugs (AEDs). We retrospectively evaluated how epilepsy was managed in a Nigerian tertiary referral center, with the goals of determining diagnostic accuracy by comparing clinical and electroencephalography (EEG) diagnoses, the appropriateness of prescribed therapy by clinician specialization, and the association between therapy and patient outcomes.Methods: We examined the medical records of 372 patients diagnosed with epilepsy in the center over a 6‐month period from 2011 to 2012. Data were obtained on methods of diagnosis, clinician specialization, therapeutic care, and patient self‐ or caregiver‐reported outcome on follow‐up visits. Interrater agreement was assessed using Cohen's κ coefficient, and the diagnoses made by nonspecialist and specialist clinicians compared using the chi‐square test.Results: Of 372 patients diagnosed with epilepsy, only one had a brain computerized tomography (CT) scan. Seventy‐six were differentially diagnosed for generalized or partial epilepsy by both clinical presentation and EEG. Low interrater agreement (κ = 0.05) was found between these methods of diagnosis. Of the 76 patients, 53 (69.7%) received therapies judged as appropriate, with no significant difference in prescription rates for appropriate therapy between nonspecialists and specialists (p = 0.536). Specific syndromic diagnoses were made only in 4% of patients, and only in patients who underwent EEG. Only three first‐generation AEDs were prescribed, with 97.6% of patients receiving carbamazepine.Significance: The discrepancy between diagnoses made on clinical features alone versus EEG diagnosis suggests that in many patients without concomitant EEG, the epileptic syndrome might have been erroneously classified, with increased risk of inappropriate treatment. Resources should be more properly directed toward increasing access to diagnostic facilities and newer generation AEDs.